Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Intrinsic Biological Variability In High-Risk-Myelodysplastic Syndrome Impacts Overall Survival (OS) In Patients Experiencing Cytogenetic Evolution Treated With Azanucleosides

Ruben Hernandez Perez, Ang Li, Sarvari Venkata Yellapragada, MBBS, MD, Matthew Zheng, Maria Otazo, Martha Mims, MD, Gustavo A. Rivero, MD

Blood (2013) 122 (21): 1537.

https://doi.org/10.1182/blood.V122.21.1537.1537

Published: 2013

Journal Articles

Time Dependent Platelet Attrition Identifies Biological Subgroup In Intermediate But Not Low-Risk Myelodysplastic Syndrome (MDS) Revised-IPSS (R-IPSS) Exhibiting Distinct Overall Survival

Gustavo A. Rivero, MD, Maria Otazo, Sarvari Venkata Yellapragada, MD, Ang Li, Matthew Zheng, Ruben Hernandez Perez, Martha Mims, MD

Blood (2013) 122 (21): 5233.

https://doi.org/10.1182/blood.V122.21.5233.5233

Published: 2013

Journal Articles

Impact Of Revised-International Prognostic Scoring System (R-IPSS) Cytogenetic-Risk Stratification In Myelodysplastic Syndrome

Maria Otazo, Sarvari Venkata Yellapragada, MBBS, MD, Matthew Zheng, Ang Li, Ruben Hernandez Perez, Gustavo A. Rivero, MD

Blood (2013) 122 (21): 5234.

https://doi.org/10.1182/blood.V122.21.5234.5234

Published: 2013

Journal Articles

Sustained Erythroid Response Associated With Red Cell Transfusion and Progressive Growth Factor Independence Is Feasible With Adjuvant Sertraline In Low-Risk Myelodysplastic Syndrome (LR-MDS)

Rui Li, MD, PhD, Matthew Zheng, Sarvari Venkata Yellapragada, MD, Ruben Hernandez Perez, Martha Mims, MD, Gustavo A. Rivero, MD

Blood (2013) 122 (21): 5235.

https://doi.org/10.1182/blood.V122.21.5235.5235

Published: 2013

Journal Articles

Selective-Serotonin-Reuptake-Inhibitors (SSRIs) In Combination With Myeloma Directed Therapy Accelerates Sentinel M-Protein Normalization In De-Novo Multiple Myeloma

Mathew Zheng, Sarvari Venkata Yellapragada, MD, Martha Mims, MD, Ruben Hernandez Perez, Gustavo A. Rivero, MD

Blood (2013) 122 (21): 5387.

https://doi.org/10.1182/blood.V122.21.5387.5387

Published: 2013

NARROW

Intrinsic Biological Variability In High-Risk-Myelodysplastic Syndrome Impacts Overall Survival (OS) In Patients Experiencing Cytogenetic Evolution Treated With Azanucleosides

Time Dependent Platelet Attrition Identifies Biological Subgroup In Intermediate But Not Low-Risk Myelodysplastic Syndrome (MDS) Revised-IPSS (R-IPSS) Exhibiting Distinct Overall Survival

Impact Of Revised-International Prognostic Scoring System (R-IPSS) Cytogenetic-Risk Stratification In Myelodysplastic Syndrome

Sustained Erythroid Response Associated With Red Cell Transfusion and Progressive Growth Factor Independence Is Feasible With Adjuvant Sertraline In Low-Risk Myelodysplastic Syndrome (LR-MDS)

Selective-Serotonin-Reuptake-Inhibitors (SSRIs) In Combination With Myeloma Directed Therapy Accelerates Sentinel M-Protein Normalization In De-Novo Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Intrinsic Biological Variability In High-Risk-Myelodysplastic Syndrome Impacts Overall Survival (OS) In Patients Experiencing Cytogenetic Evolution Treated With Azanucleosides

Time Dependent Platelet Attrition Identifies Biological Subgroup In Intermediate But Not Low-Risk Myelodysplastic Syndrome (MDS) Revised-IPSS (R-IPSS) Exhibiting Distinct Overall Survival

Impact Of Revised-International Prognostic Scoring System (R-IPSS) Cytogenetic-Risk Stratification In Myelodysplastic Syndrome

Sustained Erythroid Response Associated With Red Cell Transfusion and Progressive Growth Factor Independence Is Feasible With Adjuvant Sertraline In Low-Risk Myelodysplastic Syndrome (LR-MDS)

Selective-Serotonin-Reuptake-Inhibitors (SSRIs) In Combination With Myeloma Directed Therapy Accelerates Sentinel M-Protein Normalization In De-Novo Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only